Department of Endocrinology and Metabolism, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
J Diabetes Res. 2021 Nov 16;2021:5578216. doi: 10.1155/2021/5578216. eCollection 2021.
To study the effect of liraglutide on the thickness of epicardial adipose tissue (EAT) in type 2 diabetes mellitus (T2DM) patients with abdominal obesity.
Abdominal obesity T2DM patients with poor glycemic control were collected and treated with liraglutide. The changes of blood glucose, blood lipid, waist circumference, body mass index (BMI), and EAT thickness were compared after 3 months of treatment with liraglutide. Cardiac magnetic resonance imaging (MRI) was used to measure EAT thickness.
After 3 months of treatment with liraglutide, glycosylated hemoglobin (HbA) decreased from 9.81 ± 1.46% to 6.94 ± 1.29% (95%CI = 2.14-3.59, < 0.001). The weight decreased from 91.67 ± 16.29 kg to 87.29 ± 16.43 kg (95%CI = 2.97-5.79, < 0.001). Waist circumference before treatment was 103.69 ± 9.14 cm, and after treatment was 96.42 ± 8.42 cm (95%CI = 5.04-9.50, < 0.001). Total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) were significantly lower than those before treatment. TC decreased from 5.34 ± 1.05 mmol/L to 4.86 ± 0.97 mmol/L (95%CI = 0.15-0.82, < 0.001). TG was 1.89 (1.48-3.17) and then to 1.92 ± 0.69 ( = 0.03). LDL-C decreased from 3.39 ± 0.84 mmol/L to 3.01 ± 0.74 mmol/L (95%CI = 0.17-0.59, = 0.001). HDL-C increased by 1.7% after treatment, with no significant difference ( = 0.062). More importantly, the thickness of EAT decreased from 5.0 (5.0-7.0) mm to 3.95 ± 1.43 mm ( < 0.001) after liraglutide administered for 3 months.
Liraglutide significantly reduces EAT thickness in T2DM with abdominal obesity, which provides theoretical support for the cardiovascular benefits of liraglutide.
研究利拉鲁肽对合并腹型肥胖的 2 型糖尿病（T2DM）患者的心脏外膜脂肪组织（EAT）厚度的影响。
收集血糖控制不佳的腹型肥胖 T2DM 患者，给予利拉鲁肽治疗，比较治疗 3 个月后血糖、血脂、腰围、体质量指数（BMI）、EAT 厚度的变化，采用心脏磁共振成像（MRI）测量 EAT 厚度。
利拉鲁肽治疗 3 个月后，糖化血红蛋白（HbA）从 9.81±1.46%下降至 6.94±1.29%（95%CI=2.14-3.59，<0.001），体质量从 91.67±16.29kg 降至 87.29±16.43kg（95%CI=2.97-5.79，<0.001），腰围由治疗前的 103.69±9.14cm 降至 96.42±8.42cm（95%CI=5.04-9.50，<0.001）。治疗前总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）明显低于治疗前，TC 由 5.34±1.05mmol/L 降至 4.86±0.97mmol/L（95%CI=0.15-0.82，<0.001），TG 为 1.89（1.48-3.17）降至 1.92±0.69（=0.03），LDL-C 由 3.39±0.84mmol/L 降至 3.01±0.74mmol/L（95%CI=0.17-0.59，=0.001），HDL-C 治疗后升高 1.7%，差异无统计学意义（=0.062）。更重要的是，EAT 厚度从 5.0（5.0-7.0）mm 下降至 3.95±1.43mm（<0.001），治疗 3 个月后利拉鲁肽给药。
利拉鲁肽可显著降低合并腹型肥胖的 T2DM 患者的 EAT 厚度，为利拉鲁肽的心血管获益提供理论支持。
